A phase II study on the duration and stability of the intraocular pressure-lowering effect and tolerability of tafluprost compared with latanoprost

Journal of Ocular Pharmacology and Therapeutics

Volumn 26, Issue 1, 2010, Pages 97-104

  Traverso, Carlo E ^a   Ropo, Auli ^b   Papadia, Marina ^a   Uusitalo, Hannu ^c,d  

^a UNIVERSITY OF GENOA   (Italy)

^b Santen Oy   (Finland)

^c UNIVERSITY OF EASTERN FINLAND   (Finland)

^d TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

EYE DROPS; LATANOPROST; TAFLUPROST;

ADULT; ARTICLE; BLOOD PRESSURE; CLINICAL ARTICLE; CLINICAL TRIAL; CONJUNCTIVAL HYPEREMIA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEATH; DOSE TIME EFFECT RELATION; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; DRY EYE; EXFOLIATION SYNDROME; EYE IRRITATION; EYELID EDEMA; FEMALE; HEADACHE; HEART RATE; HUMAN; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; LACRIMATION; MALE; MULTICENTER STUDY; OCULAR PRURITUS; OPEN ANGLE GLAUCOMA; PHASE 2 CLINICAL TRIAL; PHOTOPHOBIA; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT;

DOUBLE-BLIND METHOD; EXFOLIATION SYNDROME; EYE; FEMALE; GLAUCOMA; GLAUCOMA, OPEN-ANGLE; HUMANS; INTRAOCULAR PRESSURE; MALE; OCULAR HYPERTENSION; PROSTAGLANDINS F; PROSTAGLANDINS F, SYNTHETIC; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77749279517     PISSN: 10807683     EISSN: None     Source Type: Journal    
DOI: 10.1089/jop.2009.0066     Document Type: Article

References (23)

1. World Health Organization. Causes of Blindness and Visual Impairment. Available at: www.who.int/blindness/causes/en/. Accessed on February 19, 2009.
2. The AGIS Investigators. The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual fi eld deterioration. Am. J. Ophthalmol. 130:429-440, 2000.
3. Leske, M.C., Heijl, A., Hussein, M., et al.; Early Manifest Glaucoma Trial Group. Factors for glaucoma progression and the effect of treatment: the early manifest glaucoma trial. Arch. Ophthalmol. 121:48-56, 2003.
4. Kass, M.A., Heuer, D.K., Higginbotham, E.J., et al. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch. Ophthalmol. 120:701-13; discussion 829, 2002.
5. Heijl, A., Traverso, C.E. Treatment principles and options. In: European Glaucoma Society. Terminology and Guidelines for Glaucoma. 2nd ed. Savona, Italy: Dogma Publications; 2003; p. 90-133.
6. Detry-Morel, M. Side effects of glaucoma medications. Bull. Soc. Belge Ophtalmol. 27-40, 2006.
7. Nakajima, T., Matsugi, T., Goto, W., et al. New fl uoroprostaglandin F(2alpha) derivatives with prostanoid FP-receptor agonistic activity as potent ocular-hypotensive agents. Biol. Pharm. Bull. 26:1691-1695, 2003.
8. Ota, T., Murata, H., Sugimoto, E., et al. Prostaglandin analogues and mouse intraocular pressure: effects of tafluprost, latanoprost, travoprost, and unoprostone, considering 24-hour variation. Invest. Ophthalmol. Vis. Sci. 46:2006-2011, 2005.
9. Ota, T., Aihara, M., Saeki, T., et al. The IOP-lowering effects and mechanism of action of tafluprost in prostanoid receptor-deficient mice. Br. J. Ophthalmol. 91:673-676, 2007.
10. Takagi, Y., Nakajima, T., Shimazaki, A., et al. Pharmacological characteristics of AFP-168 (tafluprost), a new prostanoid FP receptor agonist, as an ocular hypotensive drug. Exp. Eye Res. 78:767-776, 2004.
11. Sutton, A., Gilvarry, A., and Ropo, A. A comparative, placebo-controlled study of prostanoid fl uoroprostaglandin-receptor agonists tafluprost and latanoprost in healthy males. J. Ocul. Pharmacol. Ther. 23:359-365, 2007.
12. Egorov, E., and Ropo, A.; Investigators. Adjunctive use of tafluprost with timolol provides additive effects for reduction of intraocular pressure in patients with glaucoma. Eur. J. Ophthalmol. 19:214-222, 2009.
13. Santen Oy. Taflotan (tafluprost). Summary of Product Characteristics (SmPC), 2008. Available at: http://www.lakemedelsverket.se/upload/SPC-PIL/ Pdf/humspc/Taflotan%20eye%;20drops%;20solution.pdf. Accessed on February 19, 2009.
14. Larsson, L.I. Intraocular pressure over 24 hours after single-dose administration of latanoprost 0.005%; in healthy volunteers. A randomized, double-masked, placebo controlled, cross-over single center study. Acta. Ophthalmol. Scand. 79:567-571, 2001.
15. Stewart, W.C., Holmes, K.T., and Johnson, M.A. Washout periods for brimonidine 0.2%; and latanoprost 0.005%;. Am. J. Ophthalmol. 131:798-799, 2001.
16. Murphy, P.J., Lau, J.S., Sim, M.M., et al. How red is a white eye? Clinical grading of normal conjunctival hyperaemia. Eye. 21:633-638, 2007.
17. Papas, E.B. Key factors in the subjective and objective assessment of conjunctival erythema. Invest. Ophthalmol. Vis. Sci. 41:687-691, 2000.
18. Parrish, R.K., Palmberg, P., and Sheu, W.P.; XLT Study Group. A comparison of latanoprost, bimatoprost, and travoprost in patients with elevated intraocular pressure: a 12-week, randomized, masked-evaluator multicenter study. Am. J. Ophthalmol. 135:688-703, 2003.
19. Netland, P.A., Landry, T., Sullivan, E.K., et al.; Travoprost Study Group. Travoprost compared with latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension. Am. J. Ophthalmol. 132:472-484, 2001.
20. Noecker, R.S., Dirks, M.S., Choplin, N.T., et al.; Bimatoprost/ Latanoprost Study Group. A six-month randomized clinical trial comparing the intraocular pressure-lowering effi cacy of bimatoprost and latanoprost in patients with ocular hypertension or glaucoma. Am. J. Ophthalmol. 135:55-63, 2003.
21. van der Valk, R., Webers, C.A., Schouten, J.S., et al. Intraocular pressure-lowering effects of all commonly used glaucoma drugs: a meta-analysis of randomized clinical trials. Ophthalmology. 112:1177-1185, 2005.
22. Feldman, R.M. Conjunctival hyperemia and the use of topical prostaglandins in glaucoma and ocular hypertension. J. Ocul. Pharmacol. Ther. 19:23-35, 2003.
23. Reardon, G., Schwartz, G.F., and Mozaffari, E. Patient persistency with ocular prostaglandin therapy: a population-based, retrospective study. Clin. Ther. 25:1172-1185, 2003.